Information Provided By:
Fly News Breaks for March 23, 2018
AMAG
Mar 23, 2018 | 12:13 EDT
B. Riley FBR analyst David Buck believes Amag Pharmaceuticals' settlement with Sandoz mitigates the company's litigation risk over the near-term. The agreement, however, may crimp Amag's growth over the longer term, Buck tells investors in an intraday research note. He has a Neutral rating on Amag with a $23 price target.
News For AMAG From the Last 2 Days
There are no results for your query AMAG